| The leptin system: a potential target for sepsis induced immune suppression. | |
| | |
MedLine Citation:
|
PMID: 20923403 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sepsis, which is defined as a systemic inflammatory response syndrome that occurs during infection, is associated with several clinical conditions and high mortality rates. As sepsis progresses immune paralysis can become severe, leaving an already vulnerable patient ill equipped to eradicate primary or secondary infections. At present the predominant treatments for sepsis have not demonstrated convincing efficacy of decreased mortality. During sepsis, it has been observed that leptin levels initially increase but subsequently decline. A body of evidence has demonstrated that central or systemic leptin can beneficially regulate immune function. In this report expression of leptin and its receptor, signaling, and function on leukocytes will be reviewed. Furthermore, the effects mediated by central and systemic leptin during sepsis will be reviewed. Altogether, the ability of leptin to beneficially enhance inflammation and the host response during sepsis supports its use as a therapeutic agent, particularly during the latter phases of the syndrome. |
| | |
Authors:
|
Johannes Tschöp; Jonathan R Dattilo; Priya S Prakash; Kevin R Kasten; Matthias H Tschöp; Charles C Caldwell |
Related Documents
:
|
20813273 - Biomarkers for late-onset neonatal sepsis: cytokines and beyond. 15604223 - Reversal of long-term sepsis-induced immunosuppression by dendritic cells. 20145153 - Remote control of intestinal tumorigenesis by innate immunity. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Endocrine, metabolic & immune disorders drug targets Volume: 10 ISSN: 2212-3873 ISO Abbreviation: Endocr Metab Immune Disord Drug Targets Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2011-01-10 Completed Date: 2011-04-18 Revised Date: 2012-04-19 |
Medline Journal Info:
|
Nlm Unique ID: 101269157 Medline TA: Endocr Metab Immune Disord Drug Targets Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 336-47 Citation Subset: IM |
Affiliation:
|
Department of Surgery, University of Cincinnati College of Medicine, OH 45267, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cytokines / metabolism Immune Tolerance* Immunologic Factors / therapeutic use Inflammation Mediators / metabolism Leptin / metabolism*, therapeutic use Leukocytes / immunology Receptors, Leptin / metabolism Sepsis / drug therapy, immunology* Signal Transduction |
| Chemical | |
Reg. No./Substance:
|
0/Cytokines; 0/Immunologic Factors; 0/Inflammation Mediators; 0/Leptin; 0/Receptors, Leptin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PKC-? is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.
Next Document: Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory respo...